The expression of PD-L1 on the surface of tumor cells is less evident [60], suggesting that PD-1/PD-L1 inhibitors might be used in the treatment of aggressive, advanced, and/or resistant MpBCs. The gene discussed is CD274; the disease is neoplasm.